PROGNOSTIC SIGNIFICANCE OF CYTOKINES` TISSUE LEVELS IN SOME MALIGNANT TUMORS
- 作者: Zlatnik E.1, Bazaev A.1, Kochuev S.1
-
隶属关系:
- Federal Budget Institution Rostov Research Institute of Oncology
- 期: 卷 22, 编号 2-1 (2019)
- 页面: 270-271
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119741
- DOI: https://doi.org/10.31857/S102872210006597-1
- ID: 119741
如何引用文章
全文:
详细
Levels of cytokines TNF-α, IL-1β, IL-2, IL-6, IL-8, IL-10, IFN-α, IFN-γ were evaluated in samples of tumor and peritumoral tissue of 36 patients with esophageal cancer and 56 patients with skin melanoma in comparison with their clinical course. By means of ROC-analysis we showed that cytokines` levels in tissues are of some use for prognosis of the risk of the tumors` early progression. High levels of IL-1β and IL-6 in tumor, IL-1β and IL-2 in peritumoral tissue characterize the melanoma`s microenvironment as the most dangerous in course of negative prognosis. As for the esophageal cancer it is related to high amounts of IL-1β, IL-8 and IL-10 in tumor, IL-8 and TNF-α in peritumoral tissue, TNF-α and IL-10 in the resection line.
作者简介
E. Zlatnik
Federal Budget Institution Rostov Research Institute of Oncology
编辑信件的主要联系方式.
Email: elena-zlatnik@mail.ru
MD, Prof., Chief Researcher, Laboratory of Immunophenotyping of Tumors,
Rostov-on-Don
俄罗斯联邦A. Bazaev
Federal Budget Institution Rostov Research Institute of Oncology
Email: rnioi@list.ru
post-graduate student,
Rostov-on-Don
俄罗斯联邦S. Kochuev
Federal Budget Institution Rostov Research Institute of Oncology
Email: rnioi@list.ru
post-graduate student,
Rostov-on-Don
俄罗斯联邦参考
- Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014, 5, 197.
- Lippitz B. E. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013, 14, 218–228
- Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012, 12(4), 298–306
- Greenhalgh T. How to Read a Paper: The Basics of Evidence Based Medicine. Second Edition. London: BMJ, 2001. 222.